BridgeMD
Premixed glucagon/insulin solution for faster insulin absorption in Type 1 diabetes.
EU CTIS ID: 2023-510408-32-02
What this study is testing
a) To investigate if adding 100 ng glucagon/unit insulin increases the speed of absorption of SC injected insulin in patients with T1D b) To investigate if adding 100 ng glucagon/unit insulin increases the effect on glucose metabolism insulin in patients with T1D
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. T1D for at least one year.
- 2. Age 18 – 70 years.
- 3. Last known HbA1c <75 mmol/mol (< 9.0%).
- 4. Treated with an insulin pump or a hybrid artificial pancreas (AP).
You likely can't join if
- 1. Pregnant women or women trying to conceive (women will not be screened by a pregnancy test).
- 2. Any chronic disease, including psychiatric illnesses, judged incompatible with participation in the study.
- 3. Unfit for participation for any reason as judged by the investigators.
- 4. Known hypersensitivity to glucagon or to any of the excipients of the drug formulations.
- 5. Known phaeochromocytoma.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.